Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku,Timothy A. Yap,Funda Meric-Bernstam
DOI: https://doi.org/10.1038/nrclinonc.2018.28
IF: 78.8
2018-03-06
Nature Reviews Clinical Oncology
Abstract:Key PointsThe PI3K–AKT–mTOR signalling pathway, which controls multiple cellular processes including metabolism, motility, proliferation, growth, and survival, is one of the most frequently dysregulated pathways in human cancers.The PI3K–AKT–mTOR pathway can be aberrantly activated by multiple factors, including diverse oncogenic genomic alterations in PIK3CA, PIK3R1, PTEN, AKT, TSC1, TSC2, LKB1, MTOR, and other critical genes, which can serve as targets for anticancer therapy.More than 40 inhibitors of the PI3K–AKT–mTOR signalling pathway have reached different stages of clinical development, but few — temsirolimus, everolimus, idelalisib, and copanlisib — have been approved for clinical use.Limited single-agent activity, problematic levels of toxicity, and a lack of predictive biomarkers for treatment selection have all been major barriers to the clinical translation of agents that target components of the PI3K–AKT–mTOR pathway.Novel compounds and dosing schedules that have fewer off-target effects need to be developed; efforts to identify biomarkers associated with clinical activity also need to be expanded beyond PIK3CA or PTEN alterations.Finally, as demonstrated in patients with metastatic hormone-receptor-positive breast cancer, combination strategies might open viable paths to advancing PI3K–AKT–mTOR inhibitors from clinical studies to new standard-of-care treatments.
oncology